IRL-201104 is under clinical development by Revolo Biotherapeutics and currently in Phase II for Eosinophilic Esophagitis. According to GlobalData, Phase II drugs for Eosinophilic Esophagitis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the IRL-201104 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IRL-201104 overview
IRL-201104 is under development for the treatment of asthma, allergies, eosinophilic esophagitis, grass pollen allergy, seasonal allergic rhinitis, food allergy, coronavirus disease 2019 (COVID-19), coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome, ARDS Associated to Influenza Infection and atopic dermatitis. The drug candidate is a peptide derived from mycobacterium tuberculosis chaperonin 60.1. It is administered through intravenous and subcutaneous routes.
See Also:
It was also under development for dermatological indications.
Revolo Biotherapeutics overview
Revolo Biotherapeutics is developing first-in-class disease resetting therapeutics for inflammatory and immunological diseases. The company’s pipeline products including PIN201104 (1104) and IRL201805 (1805) are drug compounds derived from endogenous immunoregulatory proteins (mTB chaperonin and BiP) for the treatment of asthma and rheumatoid arthritis. It is developing novel immunomodulatory platforms that reset the immune system advancing the control and management of chronic inflammatory diseases facilitating disease modification and remission. Revolo Biotherapeutics is headquartered in Stevenage, Hertfordshire, the UK.
For a complete picture of IRL-201104’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
